2002 JUN 4 - (NewsRx.com & NewsRx.net) -- Quest Diagnostics, Inc., (DGX) has begun offering Abbott Laboratories' Vysis UroVysion DNA Probe Assay, a noninvasive method for monitoring the recurrence of bladder cancer in patients previously diagnosed with the disease.
In March 2002, the U.S. Food and Drug Administration (FDA) cleared Abbott Laboratories' use of new clinical data in the test's labeling as providing further evidence of the test's effectiveness in monitoring bladder cancer recurrence.
UroVysion can be used in conjunction with cystoscopy and is the only DNA-based test currently available for monitoring the recurrence of bladder cancer. The …
No comments:
Post a Comment